This trial evaluates safety and immunogenicity of the IDH vaccine alone or in combination with avelumab in patients with recurrent and re-resectable IDH1R132H mutant glioma, comparing these two arms to an avelumab monotherapy arm. The gene discussed is IDH2; the disease is central nervous system cancer.